Nanologica AB (OSTO:NICA) Total Liabilities: kr164.82 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NICA Nanologica AB OSTO:NICA
45 GF Score
Price kr0.47
GF Value kr4.24
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Nanologica AB Total Liabilities?

Nanologica AB OSTO:NICA +5.10% 45 Total Liabilities is kr164.82 Mil as of Mar. 2026. GuruFocus rates OSTO:NICA with a GF Score™ of 45/100 and a GF Value™ of kr4.24 (Possible Value Trap). The stock has 9 warning signs investors should review.

Nanologica AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr164.82 Mil.

Nanologica AB's quarterly Total Liabilities increased from Sep. 2025 (kr60.80 Mil) to Dec. 2025 (kr65.47 Mil) and increased from Dec. 2025 (kr65.47 Mil) to Mar. 2026 (kr164.82 Mil).

Nanologica AB's annual Total Liabilities declined from Dec. 2023 (kr79.33 Mil) to Dec. 2024 (kr68.99 Mil) and declined from Dec. 2024 (kr68.99 Mil) to Dec. 2025 (kr65.47 Mil).

Nanologica AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Total Liabilities Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.72 81.36 79.33 68.99 65.47

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.15 61.01 60.80 65.47 164.82
OSTO:NICA
45GF Score
Nanologica AB OSTO:NICA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanologica AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=36.676+(0.208+28.582
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=65.47

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=88.111-22.645
=65.47

Nanologica AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=119.445+(45.355+0.020000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=164.82

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=262.316-97.496
=164.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr164.82 Mil mean?
Nanologica AB (OSTO:NICA) has a Total Liabilities of kr164.82 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanologica AB and its competitors.
Is Nanologica AB's Total Liabilities too high?
Nanologica AB's current Total Liabilities is kr164.82 Mil. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Total Liabilities compare to VRTX and REGN?
Nanologica AB's Total Liabilities of kr164.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanologica AB and its competitors. Nanologica AB's current Total Liabilities is kr164.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current Total Liabilities is kr164.82 Mil. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Total Liabilities is kr164.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (OSTO:NICA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24. GuruFocus considers Nanologica AB to be Possible Value Trap.

Key valuation signals for OSTO:NICA:

  • Total Liabilities: kr164.82 Mil
  • GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanologica AB Business Description

Other Exchanges 4YD:Germany
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score

Get the complete analysis for OSTO:NICA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.47
Price
kr4.24
GF Value